Skip to main content
Clinical Trials/NCT03638635
NCT03638635
Terminated
Phase 4

TAP Blocks Performed With Bupivacaine Versus Liposomal Bupivacaine in Colorectal Surgery Patients: A Prospective, Cluster Randomized Trial

Inova Health Care Services6 sites in 1 country63 target enrollmentMay 14, 2018

Overview

Phase
Phase 4
Intervention
Bupivacaine
Conditions
Opioid Use
Sponsor
Inova Health Care Services
Enrollment
63
Locations
6
Primary Endpoint
In-hospital Postoperative Opioid Consumption
Status
Terminated
Last Updated
6 years ago

Overview

Brief Summary

The transversus abdominis plane (TAP) block can be used to reduce pain in patients who get abdominal surgery. TAP blocks are given with a local anesthetic. The purpose of this study is to compare pain medication usage after surgery between two different types of local anesthetic: liposomal bupivacaine and standard bupivacaine.

Detailed Description

Pain control is a factor that is central to the surgical patient's postoperative experience. Opioid pain medications are a mainstay of postoperative pain management. However, these have several adverse effects. Multimodal pain regimens to minimize opioid use have become central to enhanced recovery after surgery (ERAS) protocols. The transversus abdominis plane (TAP) block is one intervention that contributes to this regimen. Traditionally, TAP blocks are performed with local anesthetics such as bupivacaine. More recently, these have also been performed with liposomal bupivacaine, whose duration of action is much greater than regular bupivacaine (96 hours versus 8-9 hours, respectively). In this study, postoperative opioid usage will be compared between patients receiving regular bupivacaine and liposomal bupivacaine.

Registry
clinicaltrials.gov
Start Date
May 14, 2018
End Date
January 16, 2019
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • 18 years of age or older
  • Undergoing elective colectomy by surgeons of Fairfax Colon and Rectal Surgery

Exclusion Criteria

  • Allergic to local anesthetics
  • Unable to provide consent
  • On opioids at home chronically (Patients previously on a regular opioid regimen would need to be opioid-free for a period of 1 year for inclusion in the study)
  • Undergoing emergent operations
  • Undergoing loop ileostomy reversal
  • Undergoing abdominoperineal resection, pelvic exenteration, or perineal rectal prolapse repairs

Arms & Interventions

Standard Bupivacaine

Standard (0.25% bupivacaine) bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.

Intervention: Bupivacaine

Bupivacaine Liposome

Liposomal bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.

Intervention: Bupivacaine liposome

Outcomes

Primary Outcomes

In-hospital Postoperative Opioid Consumption

Time Frame: up to postoperative day 3 at 1 pm

Daily overall opioid use recorded as morphine equivalents

Secondary Outcomes

  • Pain Score(Approximately every 6 hours through postoperative day 3 by 1 pm)
  • Time to Patient Mobilization(From time of surgery until time of first patient ambulation post op. Assessed until date of discharge (usually up to 4 days after surgery).)
  • Time to Return of Bowel Function(From time of surgery until first time patient passes gas or stool per rectum or into ostomy bag. Assessed until date of discharge (usually up to 4 days after surgery).)
  • Time to Clear Liquid Diet(From time of surgery until first time patient tolerates clear liquids without nausea or vomiting. Assessed until date of discharge (usually up to 4 days after surgery).)
  • Time to Low Fiber Diet(From time of surgery until first time patient tolerates a low fiber diet without nausea or vomiting. Assessed until date of discharge (usually up to 4 days after surgery).)
  • Length of Stay(Date of surgery to date of discharge (usually up to 4 days after surgery).)
  • In-hospital Antiemetic Use(Time of transfer to post operative suite to time of discharge (usually up to 4 days after surgery).)
  • Complications(Within 30 days of surgery)
  • Readmissions(Within 30 days of hospital discharge)
  • Mortality(Within 30 days of surgery)
  • Hospitalization Costs(From date of this surgical admission to date of this surgical discharge (usually up to 4 days after surgery).)

Study Sites (6)

Loading locations...

Similar Trials